Short Interest in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Increases By 936.6%

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 79,925 shares, a growth of 936.6% from the November 30th total of 7,710 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average trading volume of 237,817 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 237,817 shares, the short-interest ratio is currently 0.3 days. Approximately 0.7% of the shares of the company are sold short.

Hong Kong Pharma Digital Technology Trading Down 1.2%

Shares of Hong Kong Pharma Digital Technology stock opened at $0.75 on Friday. Hong Kong Pharma Digital Technology has a 52-week low of $0.68 and a 52-week high of $3.79. The company’s 50-day simple moving average is $1.03 and its 200-day simple moving average is $1.23.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.